Anavex Life Sciences Corp (AVXL)

[stealthways]

273 for early stage and 371 for late stage......just a thought today(maybe science guys can ponder) I think they know 273 has a good effect for early AD (and midterm) from all the testing done to date ...
I noticed they tested 371 McGill rat study (and titled the slides) based on late stage AD (although at the end of slides they had the slide on early preventive upcoming trial mentioned ... At this stage I wonder if they are thinking for many/some patients 273 might be better for early stage (milder, and has the long lasting metabolite and insomnia benefit) and then patients at later stages AD being better suited to 371.... Deffinitely early to judge but I would say the data at this point in time does point to 273 early and 371 late stage...
At any rate, no mater who owns 273 and 371 (the same or different entity) after all research is complete...I hope 273 and 371 will be able to be used together ...or coordinated together.... I doubt they have the same pk/pd profiles and it is known that there are stark differences in
AD from patient to patient (and genetics etc)..... So there is a reasonable possibility they would be a formidable due used together; and after utilizing modern diagnostic techniques to profile each individual patient, they could then optimize the duo sigma 1 drugs for that specific patient...